Paliperidone palmitate intramuscular 6-monthly formulation in schizophrenia: a profile of its use
Funding The preparation of this review was not supported by any external funding.
Authorship and conflict of interest H. A. Blair is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Review can be found here.
Abstract The 6-monthly formulation of intramuscular paliperidone palmitate [INVEGA HAFYERA™ (USA); BYANNLI® (EU)] represents a useful and convenient therapeutic option for patients with schizophrenia who have been adequately treated with or are clinically stable on the 1- or 3-monthly formulations of intramuscular paliperidone palmitate. As demonstrated in a randomized, double-blind, multicentre, phase 3 noninferiority trial, the efficacy of 6-monthly paliperidone palmitate is noninferior to that of 3-monthly paliperidone palmitate in terms of relapse rates in clinically stable patients. Both formulations were similarly effective in controlling symptom severity. Six-monthly paliperidone palmitate is generally well tolerated, with a safety and tolerability profile consistent with that of the 3-monthly formulation.
© Springer Nature Switzerland AG 2022